Pharmacogenetic of the Salbutamol Efficacy in Asthma Crisis for Children in Emergency Department
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Asthma
- Sponsor
- Hôpital Necker-Enfants Malades
- Enrollment
- 95
- Locations
- 1
- Primary Endpoint
- pre- and post-bronchodilator FEV1 value (BDR = 100 x [post-FEV1 - pre-FEV1]/pre-FEV1)
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
this study is designed to identify the genetic factors which can be implicated in the salbutamol responsiveness for asthmatic children in pediatric emergency department
Detailed Description
Patients from 6 to 16 years old consulting for an acute asthma exacerbation and receiving a treatment by salbutamol according to the usual care could be recruited.Saliva from patient were collected using Oragen®.DNA OG-500 kit or swabs.Based on literature review, four SNP were chosen:ADBR2 gene), ARG gene, and GSNOR gene.
Investigators
Helene Chappuy
MD Ph D
Hôpital Necker-Enfants Malades
Eligibility Criteria
Inclusion Criteria
- •6-16 years old
- •asthmatic patients
- •consulting for an exacerbation in a pediatric emergency department
- •parental informed consent
Exclusion Criteria
- •comorbidity
- •peak flow no available
- •pneumonia
Outcomes
Primary Outcomes
pre- and post-bronchodilator FEV1 value (BDR = 100 x [post-FEV1 - pre-FEV1]/pre-FEV1)
Time Frame: Day 0
comparison of acute response to salbutamol calculated as the percentage difference between the pre- and post-bronchodilator FEV1 value (BDR = 100 x \[post-FEV1 - pre-FEV1\]/pre-FEV1) between the different polymorphism
Secondary Outcomes
- polymorphism on the response delay(Day 0)